Q3 2023 Business Update to Accompany Quarterly Results
Filed with ASX · · 22 pages · English
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Activities Report and Appendix 4C - September 2023 Quarter
- 1H 2023 Results Release
- 1H 2023 Results Presentation
- 1H 2023 Appendix 4D and Interim Report
- First Patient Dosed in Phase 3 Illuccix China Study
Later from Telix Pharmaceuticals
- ProstACT SELECT Study of TLX591 Positive Interim Readout
- Telix Completes Acquisition of Lightpoint Medical
- First Patient Dosed in Ph III ProstACT GLOBAL Therapy Study
- Telix Announces Proposed Acquisition of QSAM Biosciences
- Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals